Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI
    • الموضوع:
    • نبذة مختصرة :
      Alopecia areata is a type of non-scarring hair loss. The dysregulation of numerous systemic Th1 (IL-2, IFN-γ, TNF, IL-12, and IL-18), Th2 (IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17E, IL-31 and IL-33) and Th17 (IL-17, IL-17F, IL-21, IL-22, IL-23 and TGF-β) cytokines was observed in patients with alopecia areata. Positive correlations between the severity of alopecia areata and an increased serum level of various cytokines including IL-2, TNF, IL-12, IL-17, and IL-17E were reported in the literature. An increased serum level of numerous cytokines, such as IL-2, IL-6, TNF, IL-12, IL-17E, and IL-22, was described as positively correlated with the duration of the disease. Moreover, it was shown that increased pre-treatment serum level of IL-12 was a positive, while increased serum levels of IL-4 and IL-13 were negative prognostic markers for the efficacy of diphenylcyclopropenone. In conclusion, alopecia areata is associated with the dysregulation of systemic Th1, Th2 and Th17 cytokines with their role in the pathogenesis, clinical manifestations and prognosis of the disease. Available data indicate the most significant role of serum IL-2, TNF, IL-12, IL-17, and IL-17E as markers of disease activity. The serum levels IL-4, IL-12 and IL-13 may be useful as potential predictors of diphenylcyclopropenone efficacy.
    • References:
      Exp Dermatol. 2010 Feb;19(2):145-7. (PMID: 19758343)
      Int J Dermatol. 2021 Nov;60(11):1397-1404. (PMID: 34008204)
      Acta Derm Venereol. 1996 Nov;76(6):421-3. (PMID: 8982401)
      Int J Dermatol. 2016 Jun;55(6):666-72. (PMID: 26235375)
      Br J Dermatol. 2020 Jan;182(1):130-137. (PMID: 30980732)
      Allergy. 2018 Oct;73(10):1979-1988. (PMID: 29611207)
      Annu Rev Immunol. 2003;21:425-56. (PMID: 12615888)
      Br J Dermatol. 1996 Dec;135(6):942-8. (PMID: 8977716)
      Sci Rep. 2018 Apr 3;8(1):5498. (PMID: 29615652)
      Curr Opin Pharmacol. 2009 Aug;9(4):447-53. (PMID: 19481975)
      Curr Opin Immunol. 2018 Dec;55:9-14. (PMID: 30248523)
      Int J Dermatol. 2016 Aug;55(8):869-74. (PMID: 26475394)
      An Bras Dermatol. 2021 Sep-Oct;96(5):551-557. (PMID: 34281739)
      Mediators Inflamm. 2010;2010:928030. (PMID: 20300578)
      J Cosmet Dermatol. 2020 Mar;19(3):746-751. (PMID: 31301100)
      Mediators Inflamm. 2017;2017:3908061. (PMID: 28316374)
      Dermatol Clin. 2013 Jan;31(1):93-108. (PMID: 23159179)
      J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e214-e215. (PMID: 32918297)
      Cent Eur J Immunol. 2020;45(3):325-333. (PMID: 33437185)
      PLoS One. 2016 May 23;11(5):e0156002. (PMID: 27214384)
      Med Arh. 2010;64(4):212-4. (PMID: 21246917)
      Exp Dermatol. 2020 Mar;29(3):231-238. (PMID: 30047620)
      Sci Rep. 2018 Apr 27;8(1):6639. (PMID: 29703903)
      Oxid Med Cell Longev. 2020 Aug 3;2020:5693572. (PMID: 32832001)
      J Cosmet Dermatol. 2020 Jan;19(1):234-240. (PMID: 31087753)
      Dis Markers. 2019 Apr 03;2019:7901062. (PMID: 31073344)
      Dermatol Res Pract. 2010;2010:503587. (PMID: 20671941)
      Br J Dermatol. 2013 Sep;169(3):543-8. (PMID: 23607748)
      Int J Mol Sci. 2021 Mar 05;22(5):. (PMID: 33807704)
      J Eur Acad Dermatol Venereol. 2021 Feb;35(2):e128-e129. (PMID: 32780884)
      J Invest Dermatol. 1989 Jun;92(6):798-805. (PMID: 2470828)
      EMBO J. 1995 Aug 1;14(15):3654-63. (PMID: 7641685)
      Australas J Dermatol. 2019 May;60(2):163-170. (PMID: 30411329)
      Postepy Dermatol Alergol. 2019 Feb;36(1):63-69. (PMID: 30858781)
      Arch Dermatol. 1992 May;128(5):702. (PMID: 1575541)
      J Invest Dermatol. 2014 Apr;134(4):1141-1142. (PMID: 24202232)
      World J Gastroenterol. 2013 Jul 7;19(25):3931-41. (PMID: 23840137)
      Br J Dermatol. 2018 Nov;179(5):1033-1048. (PMID: 29791718)
      Exp Dermatol. 2021 Feb;30(2):278-283. (PMID: 33325128)
      Acta Microbiol Immunol Hung. 2015 Sep;62(3):275-85. (PMID: 26551570)
      J Dermatolog Treat. 2016;27(3):260-3. (PMID: 26367497)
      Mediators Inflamm. 2018 Mar 11;2018:3858032. (PMID: 29713240)
      J Autoimmun. 2019 Mar;98:74-85. (PMID: 30558963)
      Eur J Dermatol. 2004 Jan-Feb;14(1):33-6. (PMID: 14965793)
      Cytokine. 2009 Apr;46(1):7-11. (PMID: 19233684)
      BBA Clin. 2016 Mar 14;5:134-42. (PMID: 27114923)
      Nat Immunol. 2012 Jul 19;13(8):722-8. (PMID: 22814351)
      Arch Dermatol Res. 2007 Jan;298(8):397-401. (PMID: 17021766)
      Clin Exp Dermatol. 2010 Jun;35(4):409-16. (PMID: 19874320)
      J Am Acad Dermatol. 2020 Jul;83(1):123-130. (PMID: 32165196)
      J Eur Acad Dermatol Venereol. 2018 Jun;32(6):1028-1033. (PMID: 29283462)
      J Allergy Clin Immunol. 2018 Nov;142(5):1631-1634.e13. (PMID: 29981808)
      Cell Biosci. 2021 Jan 6;11(1):2. (PMID: 33407883)
      Cancer Metastasis Rev. 2006 Sep;25(3):409-16. (PMID: 16951987)
      Eur J Dermatol. 2013 May-Jun;23(3):308-18. (PMID: 23797621)
      Skin Appendage Disord. 2019 Aug;5(5):309-315. (PMID: 31559256)
      Skin Appendage Disord. 2018 Oct;4(4):286-290. (PMID: 30410898)
      J Investig Dermatol Symp Proc. 2018 Jan;19(1):S62-S64. (PMID: 29273110)
      Methods Mol Biol. 2017;1585:21-35. (PMID: 28477184)
      J Investig Dermatol Symp Proc. 2020 Nov;20(1):S58-S59. (PMID: 33099387)
      J Diabetes Res. 2018 Feb 21;2018:7209872. (PMID: 29675435)
      Acta Biochim Pol. 2016;63(1):59-63. (PMID: 26885772)
      Arch Dermatol Res. 2016 Mar;308(2):115-21. (PMID: 26796544)
      J Cosmet Dermatol. 2018 Jun;17(3):533-537. (PMID: 29707896)
      J Allergy Clin Immunol. 2015 Nov;136(5):1277-87. (PMID: 26316095)
      Exp Dermatol. 2004 Jul;13(7):435-44. (PMID: 15217364)
      J Dermatolog Treat. 2022 Feb;33(1):324-328. (PMID: 32249656)
      Exp Ther Med. 2017 Jun;13(6):2883-2887. (PMID: 28587354)
      Postepy Dermatol Alergol. 2020 Dec;37(6):904-908. (PMID: 33603607)
      Int J Immunopathol Pharmacol. 2012 Jul-Sep;25(3):781-8. (PMID: 23058031)
    • Contributed Indexing:
      Keywords: chemokine; cytokine; immunology; interleukin
    • الرقم المعرف:
      0 (Cytokines)
      0 (IL25 protein, human)
      0 (Interleukin-17)
      0 (Interleukin-2)
      0 (Tumor Necrosis Factor-alpha)
      187348-17-0 (Interleukin-12)
    • الموضوع:
      Date Created: 20211224 Date Completed: 20220117 Latest Revision: 20240820
    • الموضوع:
      20240820
    • الرقم المعرف:
      PMC8699846
    • الرقم المعرف:
      10.3390/cells10123397
    • الرقم المعرف:
      34943905